Merck, on wednesday, announced that Joseph Romanelli will lead Human Health International, and join Merck’s Executive Team, from August 1, 2022. Romanelli, in this role, will have P&L responsibility for Merck’s $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S.
Merck, in its recent statement stated, ‘He will report directly to Robert M. Davis, chief executive officer and president, Merck. As previously announced, Arpa Garay leads Human Health Global Marketing, and Jannie Oosthuizen leads Human Health U.S., both also reporting to Davis.’
“Joe’s remarkable track record of driving growth, unwavering commitment to keep patients at the center, deep knowledge of the global competitive landscape and passion for Merck’s purpose to save and improve lives make him the ideal leader for our growing and expansive international Human Health business. I’m excited to welcome Joe back to Merck, and I am confident that our company and stakeholders will greatly benefit from his leadership, delivery and contributions.”Robert M. Davis, chief executive officer and president, Merck
Romanelli rejoins Merck after serving as CEO of JiXing Pharmaceuticals, a biopharmaceutical firm based in China, since 2021. Romanelli, located in Shanghai, oversaw Merck’s business in China from 2016 until 2021.
According to Merck, Merck was one of the fastest growing multinational pharmaceutical businesses in China and China became Merck’s second-largest market during his tenure. Romanelli joined Merck in 1996 and has held positions of increasing responsibility and scope in a number of strategic and operational roles.
See the Post: